ARCHIVES

IOM Committee Focuses on Studies Needed To Protect Patients On Omics-Based Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 41 | November 4, 2011

Download PDF Visit The Full Archive

Related Articles

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

July 29, 2011

Centers Agree To Broader Phase 1 Availability; Cool to Idea Of Distributing Group C Drugs

November 16, 1990

Rauscher “Identifies” Four More Comprehensive Centers

June 21, 1974

Aranesp Approval Introduces Competition To $1.8 Billion U.S. Cancer Anemia Market

August 2, 2002

Definitions, New Categories Of Centers Suggested By Cantril

July 2, 1976

Another Feasibility Study For Women’s Wealth Trial? Yes And No; It’s ‘Class Of 84’s” Adieu

December 14, 1990